Topological and functional analysis of nonalcoholic steatohepatitis through protein interaction mapping
Gastroenterology and Hepatology from Bed to Bench,
Vol. 9 No. Supplement 1 (2016),
8 December 2016
https://doi.org/10.22037/ghfbb.v0i0.1048
Abstract
Aim: The corresponding proteins are important for network mapping since the interaction analysis can provide a new interpretation about disease underlying mechanisms as the aim of this study.
Backgroud: Nonalcoholic steatohepatitis (NASH) is one of the main causes of liver disease in the world. It has been known with many susceptible proteins that play essential role in its pathogenesis.
Methods: In this paper, protein-protein interaction (PPI) network analysis of fatty liver disease retrieved from STRING db by the application of Cytoscape Software. ClueGO analyzed the associated pathways for the selected top proteins.
Results: INS, PPARA, LEP, SREBF1, and ALB are the introduced biomarker panel for fatty liver disease.
Conclusion: It seems that pathways related to insulin have a prominent role in fatty liver disease. Therefore, investigation in this case is required to confirm the possible linkage of introduced panel and involvement of insulin pathway in the disease.
- Fatty liver disease
- Protein interaction
- Network Analysis
How to Cite
References
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.
Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519-23.
Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clinics in liver disease. 2009;13(4):511-31.
Strauss RS, Barlow SE, Dietz WH. Prevelance of abnormal serum aminotransferase values in overweight and obese adolescents. The Journal of pediatrics. 2000;136(6):727-33.
Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metabolic syndrome and related disorders. 2008;6(1):1-7.
Ludwig J, Viggiano TR, Mcgill DB, Oh B, editors. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings; 1980.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009;49(1):306-17.
Degertekin B, Ozenirler S, Elbeg S, Akyol G. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Digestive diseases and sciences. 2007;52(10):2622.
Sozio MS, Liangpunsakul S, Crabb D, editors. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Seminars in liver disease; 2010: © Thieme Medical Publishers.
Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-40.
Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. Journal of lipid research. 2011;52(4):593-617.
Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585-92.
A-Kader HH. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World Journal of Pediatrics. 2009;5(4):245-54.
Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95.
Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010;51(1):111-20.
Willebrords J, Pereira IVA, Maes M, Yanguas SC, Colle I, Van Den Bossche B. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in lipid research. 2015;59:106.
Shoulders CC, Jones E, Naoumova R. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Human molecular genetics. 2004;13(suppl 1):R149-R60.
Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. Journal of lipid research. 2009;50(1):3-21.
Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nature reviews Drug discovery. 2009;8(5):399-416.
Grønning-Wang LM, Bindesbøll C, Nebb HI. The role of liver X receptor in hepatic de novo lipogenesis and cross-talk with insulin and glucose signaling: INTECH Open Access Publisher; 2013.
Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431-2.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091-3.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non‐Alcoholic Fatty Liver Disease–Meta‐Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology. 2015.
Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42(3):665-74.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics. 2008;40(12):1461-5.
Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterology and Hepatology from bed to bench. 2016;9(2):114.
Azodi MZ, Peyvandi H, Nejad MR, Safaei A, Rostami K, Vafaee R, et al. Protein-Protein Interaction Network of Celiac Disease. Gastroenterology and Hepatology from bed to bench. 2016.
Wilkison W, Cheatham B, Walker S. Remogliflozin etabonate reduces insulin resistance and liver function enzymes: role for treatment of NASH. J Hepatol. 2015;62:S211.
Graffmann N, Ring S, Kawala M-A, Wruck W, Ncube A, Trompeter H-I, et al. Modeling nonalcoholic fatty liver disease with human pluripotent stem cell-derived immature hepatocyte-like cells reveals activation of PLIN2 and confirms regulatory functions of peroxisome proliferator-activated receptor alpha. Stem Cells and Development. 2016;25(15):1119-33.
Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30-43.
Musso G, Bo S, Cassader M, De Michieli F, Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. The American journal of clinical nutrition. 2013:ajcn. 063792.
Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology. 2004;2(3):262-5.
DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. Journal of Clinical Investigation. 1985;76(1):149.
Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology And Metabolism. 2003;284(4):E671-E8.
- Abstract Viewed: 282 times
- PDF Downloaded: 151 times